抗抑郁药与β受体阻滞剂联用:CYP2D6药物相互作用的临床证据
本研究基于加州医疗补助系统2004至2012年数据,纳入21292名使用CYP2D6底物β受体阻滞剂的成人,分析联用抗抑郁药后30天内因血流动力学不良事件住院或急诊的风险。多变量分析显示,联用中强CYP2D6抑制抗抑郁药者风险显著升高(HR 1.53,95%CI 1.03-2.81;p=0.04),而弱抑制者无显著差异。
要点
- 联用中强CYP2D6抑制抗抑郁药增加β受体阻滞剂相关血流动力学事件风险。
- 弱CYP2D6抑制抗抑郁药与风险升高无显著关联。
- 高龄、男性、高β受体阻滞剂剂量及非白人族裔亦与风险增加相关。
核心结论
- 启动某些抗抑郁药与接受β受体阻滞剂患者发生严重医疗后遗症的风险增加相关,中强CYP2D6抑制者风险更高,提示代谢性药物相互作用可能介导该风险。
研究设计与样本
- 基于加州医疗补助系统(Medi-Cal)2004至2012年连续入组成人的生存分析,纳入21292名使用主要经CYP2D6代谢的β受体阻滞剂(如美托洛尔、普萘洛尔或卡维地洛)的患者。
主要发现
- 4.3%的患者在联用抗抑郁药后30天内需住院或急诊就诊。
- 联用中强CYP2D6抑制抗抑郁药(氟西汀、帕罗西汀、度洛西汀或安非他酮)者30天内因血流动力学事件住院或急诊风险显著高于无抗抑郁药者(HR 1.53,95%CI 1.03-2.81;p=0.04)。
- 联用弱CYP2D6抑制抗抑郁药者风险无显著升高(HR 1.24;95%CI 0.82-1.88;p=0.30)。
- 高龄、男性、较高β受体阻滞剂剂量、非洲裔美国人或西班牙裔也与发病率增加相关。
临床怎么用
- 对使用美托洛尔、普萘洛尔或卡维地洛等CYP2D6底物β受体阻滞剂的患者,启动中强CYP2D6抑制抗抑郁药时应警惕血流动力学不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The β-blockers and antidepressants are two of the most commonly prescribed drug classes in the United States. Several antidepressants are potent inhibitors of cytochrome P450 2D6 liver enzymes (CYP2D6) and can increase the plasma concentrations of certain β-blockers when administered concomitantly, potentially leading to serious medical consequences such as hypotension, bradycardia, and falls. OBJECTIVE: The primary objective of this investigation was to determine whether initiating an antidepressant in patients receiving β-blockers increased the risk of hemodynamic adverse events. Our primary outcome was time to hospital admissions or emergency department (ED) visits for an International Classification of Diseases-9 diagnosis suggestive of excessive β-blockade. METHODS: We conducted a survival analysis for adults continuously enrolled in the California Medicaid system (Medi-Cal) between 2004 and 2012. Eligible patients were required to be receiving β-blocker medications that are primarily CYP2D6 substrates (e.g., metoprolol, propranolol, or carvedilol). Univariate and multivariable analyses were performed for patients who concurrently received antidepressants with β-blockers. An additional multivariable analysis analyzed the association of this combination upon hospitalizations or ED visits for all causes. RESULTS: A total of 21,292 beneficiaries met the inclusion criteria, and 4.3% of patients required hospitalization or ED visits within 30 days of co-medication. In multivariable analysis, patients receiving antidepressants with moderate to strong CYP2D6 inhibitory potential (fluoxetine, paroxetine, duloxetine, or bupropion) had a greater risk for hospitalization or ED visits for hemodynamic events than those initiated on antidepressants with weak CYP2D6 inhibition for 30 days or less when each was compared with patients receiving no antidepressants (hazard ratio [HR] 1.53, 95% confidence interval [CI] 1.03-2.81; p=0.04 vs HR 1.24; 95% CI 0.82-1.88; p=0.30). Other demographic variables associated with increased morbidity included advanced age, male sex, higher β-blocker doses, and African American race or Hispanic ethnicity. CONCLUSIONS: Results of this analysis suggest that initiation of certain antidepressants was associated with an increased risk for serious medical sequelae among patients concurrently receiving β-blockers. Greater risk was observed with antidepressants that potently inhibit the CYP2D6 enzyme, implying that increased morbidity may be mediated by a metabolic drug interaction.
引用
- Shin J, Hills NK, Finley PR, et al. Combining Antidepressants with β-Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction. Pharmacotherapy. 2020. PMID: 32342526. doi:10.1002/phar.2406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。